FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for STRIBILD, a fixed-dose combination antiretroviral therapy for HIV-1 infection from Gilead Sciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)